{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:17:27Z","timestamp":1780334247334,"version":"3.54.1"},"posted":{"date-parts":[[2023,9,29]]},"group-title":"Pharmacology and Toxicology","reference-count":45,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Prion diseases uniquely manifest in three distinct forms: inherited, sporadic, and infectious. Wild-type prions are responsible for the sporadic and infectious versions, while mutant prions cause inherited variants like fatal familial insomnia (FFI) and familial Creutzfeldt-Jakob disease (fCJD). Although some drugs can prolong prion incubation times up to four-fold in rodent models of infectious prion diseases, no effective treatments for FFI and fCJD have been found.<\/jats:p>\n                <jats:p>\n                  In this study, we evaluated the efficacy of various anti-prion drugs on newly-developed knock-in mouse models for FFI and fCJD. These models express bank vole prion protein (PrP) with the pathogenic D178N and E200K mutations. We applied various drug regimens known to be highly effective against wild-type prions\n                  <jats:italic>in vivo<\/jats:italic>\n                  as well as a brain-penetrant compound that inhibits mutant PrP\n                  <jats:sup>Sc<\/jats:sup>\n                  propagation\n                  <jats:italic>in vitro<\/jats:italic>\n                  . None of the regimens tested (Anle138b, IND24, Anle138b + IND24, cellulose ether, and PSCMA) significantly extended disease-free survival or prevented mutant PrP\n                  <jats:sup>Sc<\/jats:sup>\n                  accumulation in either knock-in mouse model, despite their ability to induce strain adaptation of mutant prions. Paradoxically, the combination of Anle138b and IND24 appeared to accelerate disease by 16% and 26% in kiBVI\n                  <jats:sup>E200K<\/jats:sup>\n                  and kiBVI\n                  <jats:sup>D178N<\/jats:sup>\n                  mice, respectively, and accelerated the aggregation of mutant PrP molecules\n                  <jats:italic>in vitro<\/jats:italic>\n                  . Our results show that anti-prion drugs originally developed to treat infectious prion diseases do not necessarily work for inherited prion diseases, and that the recombinant sPMCA is not a reliable platform for identifying compounds that target mutant prions. This work underscores the need to develop therapies and validate screening assays specifically for mutant prions.\n                <\/jats:p>","DOI":"10.1101\/2023.09.28.559951","type":"posted-content","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T11:45:13Z","timestamp":1695987913000},"source":"Crossref","is-referenced-by-count":1,"title":["Anti-prion drugs do not improve survival in knock-in models of inherited prion disease"],"prefix":"10.64898","author":[{"given":"Daniel J.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy R.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.C.","family":"Bourkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lech","family":"Kaczmarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker S.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel C.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9060-4550","authenticated-orcid":false,"given":"Surachai","family":"Supattapone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023100412200458000_2023.09.28.559951v1.1","unstructured":"Prusiner SB. Prion biology and diseases. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press; 2000."},{"key":"2023100412200458000_2023.09.28.559951v1.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.11.4611"},{"key":"2023100412200458000_2023.09.28.559951v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201544"},{"key":"2023100412200458000_2023.09.28.559951v1.4","unstructured":"Zerr I , and Schmitz M . In: Adam MP , Everman DB , Mirzaa GM , Pagon RA , Wallace SE , Bean LJH , et al. eds. GeneReviews((R)). Seattle (WA); 1993."},{"key":"2023100412200458000_2023.09.28.559951v1.5","doi-asserted-by":"publisher","DOI":"10.1021\/bi00245a003"},{"key":"2023100412200458000_2023.09.28.559951v1.6","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5560011014"},{"key":"2023100412200458000_2023.09.28.559951v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/376434a0"},{"key":"2023100412200458000_2023.09.28.559951v1.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.2.532"},{"issue":"2","key":"2023100412200458000_2023.09.28.559951v1.9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","article-title":"Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy","volume":"34","year":"2019","journal-title":"Movement disorders : official journal of the Movement Disorder Society"},{"key":"2023100412200458000_2023.09.28.559951v1.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317164110"},{"issue":"5","key":"2023100412200458000_2023.09.28.559951v1.11","doi-asserted-by":"crossref","first-page":"e1008581","DOI":"10.1371\/journal.ppat.1008581","article-title":"Emergence of prions selectively resistant to combination drug therapy","volume":"16","year":"2020","journal-title":"PLoS Pathog"},{"key":"2023100412200458000_2023.09.28.559951v1.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006045"},{"key":"2023100412200458000_2023.09.28.559951v1.13","doi-asserted-by":"crossref","unstructured":"Beauchemin KS , Rees JR , and Supattapone S . Alternating anti-prion regimens reduce combination drug resistance but do not further extend survival in scrapie-infected mice. The Journal of general virology. 2021;102(12).","DOI":"10.1099\/jgv.0.001705"},{"key":"2023100412200458000_2023.09.28.559951v1.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1090187"},{"key":"2023100412200458000_2023.09.28.559951v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature01457"},{"key":"2023100412200458000_2023.09.28.559951v1.16","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.224659"},{"key":"2023100412200458000_2023.09.28.559951v1.17","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5295.2079"},{"key":"2023100412200458000_2023.09.28.559951v1.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1998.tb00176.x"},{"issue":"12","key":"2023100412200458000_2023.09.28.559951v1.19","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1212\/WNL.40.12.1820","article-title":"Inherited human prion diseases","volume":"40","year":"1990","journal-title":"Neurology"},{"key":"2023100412200458000_2023.09.28.559951v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2009.07.026"},{"key":"2023100412200458000_2023.09.28.559951v1.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1312006110"},{"key":"2023100412200458000_2023.09.28.559951v1.22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/2051-5960-1-80","article-title":"Genetic CJD with a novel E200G mutation in the prion protein gene and comparison with E200K mutation cases","volume":"1","year":"2013","journal-title":"Acta neuropathologica communications"},{"issue":"3","key":"2023100412200458000_2023.09.28.559951v1.23","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s12013-013-9663-z","article-title":"In silico analysis of prion protein mutants: a comparative study by molecular dynamics approach","volume":"67","year":"2013","journal-title":"Cell Biochem Biophys"},{"key":"2023100412200458000_2023.09.28.559951v1.24","doi-asserted-by":"publisher","DOI":"10.1021\/bi501495j"},{"key":"2023100412200458000_2023.09.28.559951v1.25","doi-asserted-by":"crossref","unstructured":"Vallabh SM , Zou D , Pitstick R , O\u2019Moore J , Peters J , Silvius D , et al. Therapeutic Trial of anle138b in Mouse Models of Genetic Prion Disease. J Virol. 2023:e0167222.","DOI":"10.1101\/2022.10.11.511739"},{"key":"2023100412200458000_2023.09.28.559951v1.26","doi-asserted-by":"crossref","unstructured":"Mehra S , Bourkas MEC , Kaczmarczyk L , Stuart E , Arshad H , Griffin JK , et al. Convergent generation of atypical prions in knock-in mouse models of genetic prion disease. bioRxiv. 2023:2023.09.26.559572.","DOI":"10.1101\/2023.09.26.559572"},{"key":"2023100412200458000_2023.09.28.559951v1.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154604"},{"key":"2023100412200458000_2023.09.28.559951v1.28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01106-16"},{"key":"2023100412200458000_2023.09.28.559951v1.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1204498109"},{"key":"2023100412200458000_2023.09.28.559951v1.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007662"},{"key":"2023100412200458000_2023.09.28.559951v1.31","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-234-2_10"},{"issue":"1","key":"2023100412200458000_2023.09.28.559951v1.32","doi-asserted-by":"crossref","first-page":"e1011083","DOI":"10.1371\/journal.ppat.1011083","article-title":"Conformational diversity in purified prions produced in vitro","volume":"19","year":"2023","journal-title":"PLoS Pathog"},{"key":"2023100412200458000_2023.09.28.559951v1.33","doi-asserted-by":"crossref","unstructured":"Giles K , Olson SH , and Prusiner SB . Developing Therapeutics for PrP Prion Diseases. Cold Spring Harb Perspect Med. 2017;7(4).","DOI":"10.1101\/cshperspect.a023747"},{"key":"2023100412200458000_2023.09.28.559951v1.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1114-9"},{"issue":"5","key":"2023100412200458000_2023.09.28.559951v1.35","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.celrep.2019.01.064","article-title":"Rescue of Transgenic Alzheimer\u2019s Pathophysiology by Polymeric Cellular Prion Protein Antagonists","volume":"26","year":"2019","journal-title":"Cell reports"},{"issue":"4","key":"2023100412200458000_2023.09.28.559951v1.36","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s12035-018-1228-0","article-title":"IVIG Delays Onset in a Mouse Model of Gerstmann-Straussler-Scheinker Disease","volume":"56","year":"2019","journal-title":"Mol Neurobiol"},{"key":"2023100412200458000_2023.09.28.559951v1.37","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.6189-11.2012"},{"key":"2023100412200458000_2023.09.28.559951v1.38","doi-asserted-by":"crossref","unstructured":"Qin K , Zhao L , Solanki A , Busch C , and Mastrianni J . Anle138b prevents PrP plaque accumulation in Tg(PrP-A116V) mice but does not mitigate clinical disease. The Journal of general virology. 2019.","DOI":"10.1099\/jgv.0.001262"},{"key":"2023100412200458000_2023.09.28.559951v1.39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010747"},{"key":"2023100412200458000_2023.09.28.559951v1.40","doi-asserted-by":"crossref","unstructured":"Bauer S , Dittrich L , Kaczmarczyk L , Schleif M , Benfeitas R , and Jackson WS . Translatome profiling in fatal familial insomnia implicates TOR signaling in somatostatin neurons. Life Sci Alliance. 2022;5(11).","DOI":"10.26508\/lsa.202201530"},{"issue":"6","key":"2023100412200458000_2023.09.28.559951v1.41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/jnc.14877","article-title":"Cellulose ether treatment in vivo generates chronic wasting disease prions with reduced protease resistance and delayed disease progression","volume":"152","year":"2020","journal-title":"J Neurochem"},{"key":"2023100412200458000_2023.09.28.559951v1.42","doi-asserted-by":"crossref","unstructured":"Teruya K , Oguma A , Takahashi S , Watanabe-Matsui M , Tsuji-Kawahara S , Miyazawa M , et al. Anti-prion activity of cellulose ether is impaired in mice lacking pre T-cell antigen receptor alpha, T-cell receptor delta, or lytic granule function. Int Immunopharmacol. 2022;107:108672.","DOI":"10.1016\/j.intimp.2022.108672"},{"key":"2023100412200458000_2023.09.28.559951v1.43","doi-asserted-by":"crossref","unstructured":"Arshad H , Patel Z , Amano G , Li LY , Al-Azzawi ZAM , Supattapone S , et al. A single protective polymorphism in the prion protein blocks cross-species prion replication in cultured cells. J Neurochem. 2022.","DOI":"10.1111\/jnc.15739"},{"issue":"19","key":"2023100412200458000_2023.09.28.559951v1.44","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","article-title":"Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints","volume":"48","year":"2020","journal-title":"Nucleic acids research"},{"key":"2023100412200458000_2023.09.28.559951v1.45","doi-asserted-by":"crossref","unstructured":"Raymond GJ , Zhao HT , Race B , Raymond LD , Williams K , Swayze EE , et al. Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight. 2019;5(16).","DOI":"10.1172\/jci.insight.131175"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.09.28.559951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:18:06Z","timestamp":1768454286000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.09.28.559951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":45,"URL":"https:\/\/doi.org\/10.1101\/2023.09.28.559951","relation":{},"subject":[],"published":{"date-parts":[[2023,9,29]]},"subtype":"preprint"}}